Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.5650
-0.0006 (-0.11%)
Feb 24, 2026, 1:44 PM EST - Market open
Longeveron Revenue
Longeveron had revenue of $137.00K in the quarter ending September 30, 2025, a decrease of -82.28%. This brings the company's revenue in the last twelve months to $1.44M, down -22.41% year-over-year. In the year 2024, Longeveron had annual revenue of $2.39M with 237.38% growth.
Revenue (ttm)
$1.44M
Revenue Growth
-22.41%
P/S Ratio
8.40
Revenue / Employee
$57,480
Employees
25
Market Cap
12.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.39M | 1.68M | 237.38% |
| Dec 31, 2023 | 709.00K | -513.00K | -41.98% |
| Dec 31, 2022 | 1.22M | -84.00K | -6.43% |
| Dec 31, 2021 | 1.31M | -4.32M | -76.80% |
| Dec 31, 2020 | 5.63M | -10.47K | -0.19% |
| Dec 31, 2019 | 5.64M | 3.50M | 164.17% |
| Dec 31, 2018 | 2.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioLineRx | 12.74M |
| BioAtla | 11.00M |
| Moolec Science | 7.83M |
| Traws Pharma | 2.85M |
| CytoMed Therapeutics | 573.19K |
| BioCardia | 3.00K |
LGVN News
- 10 days ago - Longeveron® Appoints Stephen H. Willard as Chief Executive Officer - GlobeNewsWire
- 19 days ago - Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program - GlobeNewsWire
- 26 days ago - Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) - GlobeNewsWire
- 2 months ago - Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 - GlobeNewsWire
- 3 months ago - Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging - GlobeNewsWire
- 3 months ago - Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) - GlobeNewsWire
- 3 months ago - Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) - GlobeNewsWire
- 3 months ago - Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy - GlobeNewsWire